Man Group
TVTX icon

Man Group’s Travere Therapeutics TVTX Stock Holding History

Man Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,356
Closed -$219K – 2615
2026
Q1 		$219K Buy
+7,356
New +$220K ﹤0.01% 2286
2025
Q4 		– Sell
-29,727
Closed -$710K – 2476
2025
Q3 		$710K Sell
29,727
-109,317
-79% -$2.06M ﹤0.01% 1767
2025
Q2 		$2.06M Buy
139,044
+90,265
+185% +$1.5M ﹤0.01% 1405
2025
Q1 		$874K Sell
48,779
-39,462
-45% -$801K ﹤0.01% 1617
2024
Q4 		$1.54M Buy
88,241
+62,798
+247% +$1.11M ﹤0.01% 1391
2024
Q3 		$356K Sell
25,443
-73,219
-74% -$763K ﹤0.01% 1736
2024
Q2 		$811K Sell
98,662
-18,939
-16% -$128K ﹤0.01% 1562
2024
Q1 		$907K Buy
+117,601
New +$992K ﹤0.01% 1583
2023
Q1 		– Sell
-21,300
Closed -$453K – 1575
2022
Q4 		$448K Buy
21,300
+2,800
+15% +$59.3K ﹤0.01% 1540
2022
Q3 		$456K Buy
+18,500
New +$478K ﹤0.01% 1548
2022
Q2 		– Sell
-9,500
Closed -$245K – 2408
2022
Q1 		$245K Buy
+9,500
New +$252K ﹤0.01% 1850
2021
Q1 		– Sell
-53,777
Closed -$1.47M – 2002
2020
Q4 		$1.47M Buy
53,777
+200
+0.4% +$4.67K 0.01% 1302
2020
Q3 		$989K Buy
53,577
+4,807
+10% +$93.4K ﹤0.01% 1376
2020
Q2 		$996K Sell
48,770
-7,207
-13% -$115K 0.01% 1272
2020
Q1 		$817K Sell
55,977
-3,635
-6% -$54.7K 0.01% 1162
2019
Q4 		$846K Hold
59,612
– – ﹤0.01% 1518
2019
Q3 		$691K Sell
59,612
-300
-0.5% -$4.96K ﹤0.01% 1512
2019
Q2 		$1.2M Sell
59,912
-1,633
-3% -$32.2K ﹤0.01% 1467
2019
Q1 		$1.39M Sell
61,545
-3,067
-5% -$67.8K 0.01% 1474
2018
Q4 		$1.46M Sell
64,612
-7,130
-10% -$177K 0.01% 1334
2018
Q3 		$2.06M Buy
71,742
+11,455
+19% +$327K 0.01% 1409
2018
Q2 		$1.64M Buy
60,287
+7,375
+14% +$196K 0.01% 1441
2018
Q1 		$1.18M Buy
+52,912
New +$1.26M 0.01% 1465

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Man Group's TVTX Position: Q2 2026 in Review

Man Group sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 7,356 shares — an estimated $219K sold.

Man Group first reported a position in TVTX in Q1 2018 and held it in 23 quarters. The position peaked at $2.06M in Q3 2018. 291 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Man Group reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 7,356 Travere Therapeutics shares in Q2 2026, an estimated $219K.
  • Man Group first reported a position in Travere Therapeutics in Q1 2018 and held it in 23 quarters.
  • Man Group's Travere Therapeutics position peaked at $2.06M in Q3 2018.
  • 291 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.